FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as an…
Respiratory
-
-
Viz.ai, Sanofi and Regeneron to link for COPD management
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution…
-
Apnimed to seek approval for sleep apnoea pill after Phase III success
Apnimed’s oral sleep apnoea therapy AD109 has met the primary endpoint in a Phase III trial, with hopes to file…
-
EC approves BMS’ perioperative Opdivo and chemo for NSCLC
The European Commission (EC) has granted approval to Bristol Myers Squibb's (BMS) perioperative regimen of neoadjuvant Opdivo (nivolumab), combined with chemotherapy…
-
MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) inhaler for use with a…
-
Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the…
-
ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59
The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV) vaccines,…
-
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC)…
-
Apollomics and LaunXP agree on NSCLC treatment in Asia
Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined with an epidermal…
-
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for…
